Barclays’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-400
| Closed | -$2K | – | 6512 |
|
|
2020
Q1 | $2K | Sell |
400
-9,000
| -96% | -$79.3K | ﹤0.01% | 6053 |
|
|
2019
Q4 | $114K | Buy |
9,400
+7,900
| +527% | +$86.3K | ﹤0.01% | 5410 |
|
|
2019
Q3 | $17K | Sell |
1,500
-22,500
| -94% | -$237K | ﹤0.01% | 6254 |
|
|
2019
Q2 | $240K | Buy |
24,000
+19,200
| +400% | +$207K | ﹤0.01% | 4950 |
|
|
2019
Q1 | $62K | Sell |
4,800
-8,100
| -63% | -$121K | ﹤0.01% | 5722 |
|
|
2018
Q4 | $196K | Buy |
12,900
+9,000
| +231% | +$171K | ﹤0.01% | 4590 |
|
|
2018
Q3 | $78K | Buy |
3,900
+1,500
| +63% | +$34.1K | ﹤0.01% | 5780 |
|
|
2018
Q2 | $47K | Sell |
2,400
-32,400
| -93% | -$717K | ﹤0.01% | 5681 |
|
|
2018
Q1 | $701K | Buy |
34,800
+5,600
| +19% | +$94.7K | ﹤0.01% | 3610 |
|
|
2017
Q4 | $387K | Sell |
29,200
-78,600
| -73% | -$1.19M | ﹤0.01% | 4109 |
|
|
2017
Q3 | $1.99M | Buy |
107,800
+5,400
| +5% | +$101K | ﹤0.01% | 2373 |
|
|
2017
Q2 | $1.88M | Buy |
102,400
+99,500
| +3,431% | +$1.97M | ﹤0.01% | 2307 |
|
|
2017
Q1 | $65K | Sell |
2,900
-11,600
| -80% | -$278K | ﹤0.01% | 5184 |
|
|
2016
Q4 | $505K | Sell |
14,500
-26,100
| -64% | -$780K | ﹤0.01% | 3366 |
|
|
2016
Q3 | $995K | Sell |
40,600
-6,500
| -14% | -$162K | ﹤0.01% | 2625 |
|
|
2016
Q2 | $1.13M | Buy |
47,100
+43,300
| +1,139% | +$993K | ﹤0.01% | 2510 |
|
|
2016
Q1 | $87K | Buy |
3,800
+3,700
| +3,700% | +$87.8K | ﹤0.01% | 4449 |
|
|
2015
Q4 | $3K | Sell |
100
-1,100
| -92% | -$35.5K | ﹤0.01% | 5712 |
|
|
2015
Q3 | $47K | Sell |
1,200
-4,200
| -78% | -$261K | ﹤0.01% | 5042 |
|
|
2015
Q2 | $373K | Buy |
5,400
+3,200
| +145% | +$201K | ﹤0.01% | 3707 |
|
|
2015
Q1 | $119K | Buy |
2,200
+800
| +57% | +$38.1K | ﹤0.01% | 4730 |
|
|
2014
Q4 | $59K | Sell |
1,400
-98,800
| -99% | -$3.57M | ﹤0.01% | 5597 |
|
|
2014
Q3 | $3.11M | Buy |
100,200
+77,200
| +336% | +$1.65M | ﹤0.01% | 2251 |
|
|
2014
Q2 | $460K | Buy |
23,000
+13,300
| +137% | +$246K | ﹤0.01% | 4058 |
|
|
2014
Q1 | $184K | Buy |
9,700
+8,700
| +870% | +$185K | ﹤0.01% | 4866 |
|
|
2013
Q4 | $24K | Sell |
1,000
-1,100
| -52% | -$25.9K | ﹤0.01% | 6607 |
|
|
2013
Q3 | $44K | Sell |
2,100
-5,500
| -72% | -$130K | ﹤0.01% | 6134 |
|
|
2013
Q2 | $169K | Buy |
+7,600
| New | +$167K | ﹤0.01% | 5344 |
|
Barclays's AMAG Position: Q4 2020 in Review
Barclays sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 38,001 shares — an estimated $357K sold.
Barclays first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $2.65M in Q3 2014. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Barclays reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Barclays sold 38,001 AMAG Pharmaceuticals shares in Q4 2020, an estimated $357K.
- Barclays first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Barclays's AMAG Pharmaceuticals position peaked at $2.65M in Q3 2014.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.